A journey to produce platelets in vitro

Allogeneic platelet transfusions protect patients from bleeding episodes and also make aggressive medical procedures such as those involving marrow transplants requiring chemotherapy and/or radiotherapy possible. These patients are dependent upon an unfailing supply of platelets that can sometimes be in short supply due to high demands coupled with an extremely short expiration date for platelet products of only 5 days. One approach that is under investigation to overcome platelet shortages is to harness the extraordinary capabilities of stem cells to proliferate and differentiate into various cell types and to use this ability to specifically produce clinical scale quantities of functional platelets in bioreactors. To accomplish such an enormous and complex task requires an appreciation of the regulatory mechanisms that occur during the development of megakaryocytes (MKs) and the subsequent biogenesis of functional platelets from mature MKs. This means understanding the complex network of intracellular and extracellular regulatory mechanisms that act at each phase of a developmental process that ushers stem cells along the MK lineage to produce billions of platelets per day in a healthy individual.

[1]  J. Goldman,et al.  Hematology: basic principles and practice , 2013, Bone Marrow Transplantation.

[2]  D. Discher,et al.  Myosin-II inhibition and soft 2D matrix maximize multinucleation and cellular projections typical of platelet-producing megakaryocytes , 2011, Proceedings of the National Academy of Sciences.

[3]  J. Reems,et al.  Distinct functional effects for dynamin 3 during megakaryocytopoiesis. , 2011, Stem cells and development.

[4]  D. Marks,et al.  Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution. , 2011, Cryobiology.

[5]  N. Pineault,et al.  Glycoprotein Ibα receptor instability is associated with loss of quality in platelets produced in culture. , 2011, Stem cells and development.

[6]  E. Hahm,et al.  Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice , 2011, Cell Research.

[7]  Ashutosh Kumar,et al.  In vitro function of random donor platelets stored for 7 days in composol platelet additive solution , 2011, Asian journal of transfusion science.

[8]  S. Slichter,et al.  Extended storage of platelet‐rich plasma–prepared platelet concentrates in plasma or Plasmalyte , 2010, Transfusion.

[9]  H. Gulliksson,et al.  Storage of buffy‐coat‐derived platelets in additive solutions: in vitro effects on platelets stored in reformulated PAS supplied by a 20% plasma carry‐over , 2010, Vox sanguinis.

[10]  J. Reems,et al.  In vitro megakaryocyte production and platelet biogenesis: state of the art. , 2010, Transfusion medicine reviews.

[11]  D. Baruch,et al.  Exposure of human megakaryocytes to high shear rates accelerates platelet production. , 2009, Blood.

[12]  N. Kotov,et al.  Prolonged continuous in vitro human platelet production using three-dimensional scaffolds. , 2009, Experimental hematology.

[13]  F. D. di Summa,et al.  Dynamin 3 participates in the growth and development of megakaryocytes. , 2008, Experimental hematology.

[14]  W. Vainchenker,et al.  Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. , 2008, Blood.

[15]  H. Nakauchi,et al.  Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. , 2008, Blood.

[16]  Joseph E Italiano,et al.  Dynamic Visualization of Thrombopoiesis Within Bone Marrow , 2007, Science.

[17]  D. Bluteau,et al.  From hematopoietic stem cells to platelets , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  T. Takayama,et al.  Ex Vivo Large‐Scale Generation of Human Platelets from Cord Blood CD34+ Cells , 2006, Stem cells.

[19]  L. Cantley,et al.  Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. , 2006, Blood.

[20]  J. Reems,et al.  A novel strategy for generating platelet-like fragments from megakaryocytic cell lines and human progenitor cells. , 2005, Blood cells, molecules & diseases.

[21]  G. Kōsaki.  In Vivo Platelet Production from Mature Megakaryocytes: Does Platelet Release Occur via Proplatelets? , 2005, International journal of hematology.

[22]  J. Reems,et al.  Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656. , 2004, Blood.

[23]  K. Addicks,et al.  Neurally selected embryonic stem cells induce tumor formation after long-term survival following engraftment into the subretinal space. , 2004, Investigative ophthalmology & visual science.

[24]  J. Reems,et al.  Gene expression profile of primary human CD34+CD38lo cells differentiating along the megakaryocyte lineage. , 2004, Experimental hematology.

[25]  V. Broudy,et al.  AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. , 2004, Cytokine.

[26]  J. Reems,et al.  Cord blood units collected at a remote site: a collaborative endeavor to collect umbilical cord blood through the Hawaii Cord Blood Bank and store the units at the Puget Sound Blood Center , 2004, Transfusion.

[27]  J. Reems,et al.  Identification and activation of Src family kinases in primary megakaryocytes. , 2003, Experimental hematology.

[28]  H. Miyazaki,et al.  Production of functional platelets by differentiated embryonic stem (ES) cells in vitro. , 2003, Blood.

[29]  R. Shivdasani,et al.  Megakaryocytes and beyond: the birth of platelets , 2003, Journal of thrombosis and haemostasis : JTH.

[30]  R. Lemieux,et al.  Preferential ex vivo expansion of megakaryocytes from human cord blood CD34+-enriched cells in the presence of thrombopoietin and limiting amounts of stem cell factor and Flt-3 ligand. , 2003, Journal of hematotherapy & stem cell research.

[31]  M. McNiven,et al.  Dynamin at the actin-membrane interface. , 2003, Current opinion in cell biology.

[32]  P. Han,et al.  Enhanced expansion and maturation of megakaryocytic progenitors by fibronectin. , 2002, Cytotherapy.

[33]  J. Reems,et al.  Umbilical cord blood progeny cells that retaina CD34+ phenotype after ex vivo expansion have less engraftment potential than unexpanded CD34+ cells , 2001, Transfusion.

[34]  J. Reems,et al.  Serum supplement, inoculum cell density, and accessory cell effects are dependent on the cytokine combination selected to expand human HPCs ex vivo , 2000, Transfusion.

[35]  U Magrini,et al.  Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. , 2000, Nature genetics.

[36]  T. Ortel,et al.  Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly , 2000, Nature Genetics.

[37]  C. Philipp,et al.  Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. , 2000, The American journal of pathology.

[38]  The May-HegglinFechtner Syndrome Consortium,et al.  Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes , 2000, Nature Genetics.

[39]  G. Ehninger,et al.  Defining Optimum Conditions for the Ex Vivo Expansion of Human Umbilical Cord Blood Cells. Influences of Progenitor Enrichment, Interference with Feeder Layers, Early‐Acting Cytokines and Agitation of Culture Vessels , 1999, Stem cells.

[40]  W. Vainchenker,et al.  Endomitosis of human megakaryocytes are due to abortive mitosis. , 1998, Blood.

[41]  W. Piacibello,et al.  Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation , 1998, Leukemia.

[42]  J. Case,et al.  Cytokine mediated expansion of human umbilical cord blood CD34+ cells: comparison of the use of partially purified and pure CD34+ target cells. , 1997, Hematology and cell therapy.

[43]  W. Piacibello,et al.  Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. , 1997, Blood.

[44]  I. Mcniece,et al.  Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. , 1997, Journal of hematotherapy.

[45]  N. Gorin,et al.  The ex vivo expansion capacity of normal human bone marrow cells is dependent on experimental conditions: role of the cell concentration, serum and CD34+ cell selection in stroma-free cultures. , 1997, Hematology and cell therapy.

[46]  N. Komatsu,et al.  Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO. , 1996, Blood.

[47]  K. Kellar,et al.  Flow Cytometric Analysis of Megakaryocyte‐Associated Antigens on CD34 Cells and Their Progeny in Liquid Culture , 1996, Stem cells.

[48]  S. Rafii,et al.  Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. , 1995, Blood.

[49]  Esther,et al.  Platelets Generated in Vitro from Proplatelet-displaying Human Megakaryocytes Are Functional Isolation of Cd34+ Progenitor Cells from Peripheral Blood , 2022 .

[50]  P. Lansdorp,et al.  Ontogeny-related changes in proliferative potential of human hematopoietic cells , 1993, The Journal of experimental medicine.

[51]  D. Zucker‐Franklin,et al.  Thrombocytopoiesis--analysis by membrane tracer and freeze-fracture studies on fresh human and cultured mouse megakaryocytes , 1984, The Journal of cell biology.

[52]  R. P. Becker,et al.  The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; a scanning electron microscopic investigation. , 1976, The American journal of anatomy.

[53]  J. Hendry,et al.  The relative spatial distributions of CFUs and CFUc in the normal mouse femur. , 1975, Blood.

[54]  W. Crosby,et al.  Circulating megakaryocytes and platelet release in the lung. , 1965, Blood.